Other
Valeant pitches potential eye drug, research focus
Valeant Pharmaceuticals is drawing attention to a potential glaucoma treatment and its focus on product development, as the Canadian drugmaker continues to build its case to investors for a takeover of Botox-maker Allergan.
Sep 25, 2014
0
0
